Abstract：
The \"2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage\" replaces the 2012 \"Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage.\" The 2023 guideline is intended to provide patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with aneurysmal subarachnoid hemorrhage.
A comprehensive search for literature published since the 2012 guideline, derived from research principally involving human subjects, published in English, and indexed in MEDLINE, PubMed, Cochrane Library, and other selected databases relevant to this guideline, was conducted between March 2022 and June 2022. In addition, the guideline writing group reviewed documents on related subject matter previously published by the American Heart Association. Newer studies published between July 2022 and November 2022 that affected recommendation content, Class of Recommendation, or Level of Evidence were included if appropriate. Structure: Aneurysmal subarachnoid hemorrhage is a significant global public health threat and a severely morbid and often deadly condition. The 2023 aneurysmal subarachnoid hemorrhage guideline provides recommendations based on current evidence for the treatment of these patients. The recommendations present an evidence-based approach to preventing, diagnosing, and managing patients with aneurysmal subarachnoid hemorrhage, with the intent to improve quality of care and align with patients\' and their families\' and caregivers\' interests. Many recommendations from the previous aneurysmal subarachnoid hemorrhage guidelines have been updated with new evidence, and new recommendations have been created when supported by published data.
A comprehensive search for literature published since the 2012 guideline, derived from research principally involving human subjects, published in English, and indexed in MEDLINE, PubMed, Cochrane Library, and other selected databases relevant to this guideline, was conducted between March 2022 and June 2022. In addition, the guideline writing group reviewed documents on related subject matter previously published by the American Heart Association. Newer studies published between July 2022 and November 2022 that affected recommendation content, Class of Recommendation, or Level of Evidence were included if appropriate. Structure: Aneurysmal subarachnoid hemorrhage is a significant global public health threat and a severely morbid and often deadly condition. The 2023 aneurysmal subarachnoid hemorrhage guideline provides recommendations based on current evidence for the treatment of these patients. The recommendations present an evidence-based approach to preventing, diagnosing, and managing patients with aneurysmal subarachnoid hemorrhage, with the intent to improve quality of care and align with patients\' and their families\' and caregivers\' interests. Many recommendations from the previous aneurysmal subarachnoid hemorrhage guidelines have been updated with new evidence, and new recommendations have been created when supported by published data.
摘要：
目的：“2023年动脉瘤性蛛网膜下腔出血患者治疗指南”取代了2012年“动脉瘤性蛛网膜下腔出血患者治疗指南”。“2023年指南旨在为临床医生提供以患者为中心的建议，诊断,并处理动脉瘤性蛛网膜下腔出血患者。
方法：全面搜索自2012年指南以来发表的文献，来自主要涉及人类受试者的研究，以英文出版,并在MEDLINE中索引，PubMed,科克伦图书馆,以及与本指南相关的其他选定数据库，于2022年3月至2022年6月进行。此外,指南编写小组审查了美国心脏协会以前发表的相关主题文件.2022年7月至2022年11月之间发表的影响推荐内容的最新研究，推荐类,或证据水平包括在适当的情况下。结构：动脉瘤性蛛网膜下腔出血是一种重大的全球公共卫生威胁，是一种严重的病态和通常致命的疾病。2023年动脉瘤性蛛网膜下腔出血指南根据目前的证据为这些患者的治疗提供了建议。这些建议提出了一种基于证据的方法来预防，诊断,并管理动脉瘤性蛛网膜下腔出血患者，旨在提高护理质量，并符合患者及其家人和护理人员的利益。以前的动脉瘤性蛛网膜下腔出血指南的许多建议已经更新了新的证据，并且在发布的数据支持下创建了新的建议。
方法：全面搜索自2012年指南以来发表的文献，来自主要涉及人类受试者的研究，以英文出版,并在MEDLINE中索引，PubMed,科克伦图书馆,以及与本指南相关的其他选定数据库，于2022年3月至2022年6月进行。此外,指南编写小组审查了美国心脏协会以前发表的相关主题文件.2022年7月至2022年11月之间发表的影响推荐内容的最新研究，推荐类,或证据水平包括在适当的情况下。结构：动脉瘤性蛛网膜下腔出血是一种重大的全球公共卫生威胁，是一种严重的病态和通常致命的疾病。2023年动脉瘤性蛛网膜下腔出血指南根据目前的证据为这些患者的治疗提供了建议。这些建议提出了一种基于证据的方法来预防，诊断,并管理动脉瘤性蛛网膜下腔出血患者，旨在提高护理质量，并符合患者及其家人和护理人员的利益。以前的动脉瘤性蛛网膜下腔出血指南的许多建议已经更新了新的证据，并且在发布的数据支持下创建了新的建议。
